Who are KetoNaph's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ibuprofen 2%, Ginger-ibuprofen, Experimental: Aspirin monotherapy, Ibuprofen, Hydrocortisone, EC Aspirin 325, Ibuprofen group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketonaph.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

KetoNaph — Competitive Intelligence Brief

KetoNaph (KetoNaph) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Ophthalmology.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

KetoNaph (KetoNaph) — Bausch & Lomb Incorporated. KetoNaph is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
KetoNaph TARGET	KetoNaph	Bausch & Lomb Incorporated	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Ibuprofen 2%	Ibuprofen 2%	Berlin-Chemie AG Menarini Group	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Ginger-ibuprofen	Ginger-ibuprofen	Ferrosan AS	marketed	NSAID with herbal adjunct	COX-1, COX-2 (ibuprofen component); multiple inflammatory pathways (ginger component)
Experimental: Aspirin monotherapy	Experimental: Aspirin monotherapy	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Nonsteroidal anti-inflammatory drug (NSAID) / Antiplatelet agent	COX-1, COX-2
Ibuprofen, Hydrocortisone	Ibuprofen, Hydrocortisone	X-pert Med GmbH	marketed	NSAID + corticosteroid combination	COX-1, COX-2, glucocorticoid receptor
EC Aspirin 325	EC Aspirin 325	POZEN	marketed	Antiplatelet agent / NSAID	Cyclooxygenase (COX-1, COX-2)
Ibuprofen group	Ibuprofen group	University of Salamanca	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

Università degli Studi di Brescia · 4 drugs in this class
Bausch & Lomb Incorporated · 4 drugs in this class
Bayer · 3 drugs in this class
Pfizer · 3 drugs in this class
Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
Organon and Co · 3 drugs in this class
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
Bezmialem Vakif University · 2 drugs in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KetoNaph — Competitive Intelligence Brief. https://druglandscape.com/ci/ketonaph. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab